文献速递MDS 与骨髓增殖性肿瘤

MPN干扰素α与羟基脲随机试验的基因组分析揭示突变特异性反应

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.
PubMed 文献 · Blood Adv · 2022-01-01

基于DALIAH随机3期试验,对202例MPN患者治疗前及135例治疗24个月后的样本进行120基因靶向NGS,评估完全临床血液学反应与分子反应关联。IFNα治疗的JAK2突变患者中达CHR者JAK2 VAF降幅更大,CALR VAF无显著下降,DNMT3A突变在IFNα组更常见且富集于未达CHR者。

要点

  • IFNα治疗的JAK2突变MPN患者达CHR者JAK2 VAF显著下降。
  • CALR突变患者达CHR者CALR VAF无显著下降。
  • IFNα治疗中DNMT3A突变更常见且与未达CHR相关。

核心结论

  • IFNα治疗24个月时MPN呈现突变特异性分子反应模式:JAK2与CALR突变反应不同,DNMT3A突变克隆在治疗中出现。

研究设计与样本

  • DALIAH随机对照3期试验(NCT01387763)中,对202例MPN患者治疗前样本和135例治疗24个月后样本进行120基因靶向NGS。

主要发现

  • IFNα治疗的JAK2突变患者中,达CHR者JAK2 VAF中位数从0.29降至0.07(P < .0001),未达CHR者从0.27降至0.14(P < .0001)。
  • 达CHR或未达CHR者CALR VAF均无显著下降。
  • 治疗中出现DNMT3A突变在IFNα组比羟基脲组更常见(P = .04),且在IFNα未达CHR者中显著富集(P = .02)。
  • TET2、DNMT3A或ASXL1突变与既往卒中显著相关(年龄校正OR 5.29,95%CI 1.59-17.54,P = .007),TET2单独突变亦相关(年龄校正OR 3.03,95%CI 1.03-9.01,P = .044)。

临床怎么用

  • MPN患者接受IFNα治疗时,JAK2突变VAF动态可辅助评估分子反应,CALR突变VAF下降不明显。
  • 治疗中出现DNMT3A突变可能提示IFNα反应不佳,需关注克隆演变。
  • TET2、DNMT3A或ASXL1突变患者应评估既往卒中史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although somatic mutations influence the pathogenesis, phenotype, and outcome of myeloproliferative neoplasms (MPNs), little is known about their impact on molecular response to cytoreductive treatment. We performed targeted next-generation sequencing (NGS) on 202 pretreatment samples obtained from patients with MPN enrolled in the DALIAH trial (A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms; #NCT01387763), a randomized controlled phase 3 clinical trial, and 135 samples obtained after 24 months of therapy with recombinant interferon-alpha (IFNα) or hydroxyurea. The primary aim was to evaluate the association between complete clinicohematologic response (CHR) at 24 months and molecular response through sequential assessment of 120 genes using NGS. Among JAK2-mutated patients treated with IFNα, those with CHR had a greater reduction in the JAK2 variant allele frequency (median, 0.29 to 0.07; P < .0001) compared with those not achieving CHR (median, 0.27 to 0.14; P < .0001). In contrast, the CALR variant allele frequency did not significantly decline in those achieving CHR or in those not achieving CHR. Treatment-emergent mutations in DNMT3A were observed more commonly in patients treated with IFNα compared with hydroxyurea (P = .04). Furthermore, treatment-emergent DNMT3A mutations were significantly enriched in IFNα-treated patients not attaining CHR (P = .02). A mutation in TET2, DNMT3A, or ASXL1 was significantly associated with prior stroke (age-adjusted odds ratio, 5.29; 95% confidence interval, 1.59-17.54; P = .007), as was a mutation in TET2 alone (age-adjusted odds ratio, 3.03; 95% confidence interval, 1.03-9.01; P = .044). At 24 months, we found mutation-specific response patterns to IFNα: (1) JAK2- and CALR-mutated MPN exhibited distinct molecular responses; and (2) DNMT3A-mutated clones/subclones emerged on treatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Knudsen TA, Skov V, Stevenson K, et al. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses. Blood Adv. 2022. PMID: 34507355. doi:10.1182/bloodadvances.2021004856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。